1519 - Tisagenlecleucel (CTL019) for treatment of refractory CD19-positive leukaemia and lymphoma

Page last updated: 03 April 2018

Application Detail

Status

Open

Description of Medical Service

Tisagenlecleucel is an autologous, murine anti-CD19 chimeric antigen receptor T cell (CAR-T) therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.

Description of Medical Condition

Acute lymphoblastic leukaemia (ALL) is the malignant proliferation of lymphoid progenitor cells in the bone marrow.

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and common subtype of Non-Hodgkin lymphoma (NHL).

Reason for Application

New non-MBS item

Medical Service Type

Hybrid health technology

Previous Application Number

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 842 KB)
Application Form (Word 498 KB)

Consultation Survey

Consultation Survey (PDF 113 KB)
Consultation Survey (Word 508 KB)

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

12-13 April 2018

ESC

-

MSAC

-